Pfizer Inc., San Diego, CA 92121, United States of America.
Tox Path Specialists, LLC, Frederick, MD 21701, United States of America.
Auton Neurosci. 2019 May;218:51-53. doi: 10.1016/j.autneu.2019.02.004. Epub 2019 Feb 23.
Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of sympathetic ganglia showed decreased ganglia volume, decreased neuronal size, and increased glial cell density compared with controls after 3 tanezumab treatments. Using stereological techniques to quantify glial cells, the present 26-week study found no significant difference after weekly treatments in total cervicothoracic ganglia satellite glial cell number between placebo- or tanezumab-treated cynomolgus monkeys. These findings suggest that tanezumab treatment does not result in a true gliosis in sympathetic ganglia.
替扎尼定，一种人源化单克隆抗神经生长因子抗体，在慢性疼痛的 III 期临床试验中显示出疗效和安全性。在一项为期 24 周的非人类灵长类动物研究中，与对照组相比，替扎尼定治疗 3 次后，交感神经节的形态学观察显示神经节体积减小、神经元大小减小和神经胶质细胞密度增加。使用体视学技术定量神经胶质细胞，本项为期 26 周的研究发现，每周给予替扎尼定或安慰剂治疗的食蟹猴颈椎胸段交感神经节卫星神经胶质细胞数量无显著差异。这些发现表明，替扎尼定治疗不会导致交感神经节发生真正的神经胶质增生。
